Articles

Carl Zeiss Meditec has announced that ReLEx, the first femtosecond-only method of laser vision correction, is now available for sale outside the United States.1 ReLEx is a new application that allows ophthalmic surgeons to perform a variety of complete laser vision correction procedures using only the VisuMax Femtosecond laser.

Scientists from the Mayo Clinic and Mayo Foundation in the USA have studied 135 patients with intermittent exotropia, where the eye turns outwards while looking at an object, over a 20-year period.

Heidelberg Engineering is introducing SPECTRALIS, then office-based imaging device for tracking and measuring axonal change, at the 2010 meeting of the American Academy of Neurology in Toronto.

A rare opportunity to acquire a 500-page hand-written manuscript of prominent case studies of eye injuries and diseases at Moorfields Hospital is now possible

pSivida Corp. a developer of ophthalmic sustained release drug delivery products, has said that a recently-published peer reviewed scientific paper showed that a sustained release Durasert drug delivery device releasing the steroid fluocinolone acetonide (FA) in the back of the eye preserved retinal function in a retinitis pigmentosa model.

Oraya Therapeutics has been granted the CE mark for its IRay system, which its researchers say can deliver low-energy X-rays to treat wet AMD.

Highlights from an expert roundtable meeting can be found in the April issue of Ophthalmology Times Europe.

The Review of Ophthalmology recently published a survey amongst surgeons which indicates that toric IOLs are becoming more popular for managing astigmastism in cataract patients. The results also demonstrated a move away from bimanual surgery and the mixing of presbyopic IOLs.

In the latest issue of Clinical Ophthalmology T Fukuchi et al., found that tectonic corneal grafting is a reliable and final surgical method to improve severe cases of hypotony maculopathy or bleb leak after MMC trabeculectomy.

The findings of a case report in Cognitive and Behavioral Neurology may support its authors hypothesis that the primary visual cortex, in which retinal spatial geometry is preserved, is not critical for visual imagery.

Joe Lovett's film, Going Blind will be screened at the World Ophthalmology Congress in Berlin in June. Ophthalmology Times Europe strongly recommends that all doctors put this on their schedule if they are visiting the congress.

Medicare patients in the United States are 5.5 times more likely to get cataract surgery than those who receive their care from the Department of Veterans Affairs, according to a study reported in the March 2010 issue of the American Journal of Medical Quality

The talents of the Australasian and Asia Pacific cataract and refractive surgeons associations will come together in their joint meeting on 1st ? 4th July 2010 at the Cairns Convention Centre in Australia.

> New research from the UK shows that OptiveTM eye drops have a significantly better effect on conjunctival tissues of patients with mild to moderate dry eye compared with Hylocomod (Na-Hyaluronate) eyedrops1, according to a company media statement.

HM Revenue & Customs (HMRC) has a Super Podcast, to alert ophthalmic businesses to major changes in the way they file and pay VAT, PAYE and corporation tax.

An overview of the latest natural products found to be beneficial for preventing and treating AMD was provided by Dr Bernstein during retina subspecialty day at the annual meeting of the American Academy of Ophthalmology.

Dennis S.C. Lam, MD, of Hong Kong and Stefan Seregard, MD, of Sweden have been appointed to serve a one-year term on the American Academy of Ophthalmology's (AAO) Board of Trustees.

Dr Bryan Lee, JD is a second-year resident at the Wilmer Eye Institute. He gives the Opthalmology Times Group his take on the recent AAO meeting.

Used for the treatment of blepharitis, AZASITE (azitthromycin ophthalmic solution) from Inspire Pharmaceuticals Inc., was used in two clinical trials in patients with anterior blepharitis. One trial had a two-week treatment period, the other trial a four-week treatment period.

In results due to be presented at the ARVO meeting in May Retina Implant says its first human clinical trial has exceeded its expectations with some patients able to see objects and shapes so clearly they were able to combine letters to form words and recognize foreign objects.

Santen Pharmaceutical Co., Ltd., the Japanes ophthalmic pharmaceutical company, has announced that Adrienne Graves, PhD, president and chief executive officer (CEO) of its wholly-owned US subsidiary, Santen Inc., has resigned...

Former executives of Schering-Plough, Fred Hassan and Brent Saunders, have taken over the helm at Bausch & Lomb as chairman and CEO respectively.

LEEDS, England -- Ultralase, the vision correction specialist, presented its first set of results for a new treatment, Ultraelite, at the recent Winter meeting of the European Society of Cataract and Refractive Surgeons in Budapest.

One year post-surgery, patients who underwent Descemet's stripping automated endothelial keratoplasty (DSAEK) experienced greater cell loss overall compared to those who underwent penetrating keratoplasty (PKP), according to a new analysis of data collected from the Cornea Donor Study (CDS) Investigator Group's 2008 Specular Microscopy Ancillary Study (SMAS).

Dr Ludwin Monz is now the new CEO of Carl Zeiss Meditec, having taken over from Dr Michael Kaschke. Kaschke has been elected back to the Supervisory Board and was appointed its Chairman in a subsequent Supervisory Board meeting.

Last year a human trial involving administering gene therapy to Leber's congenital amaurosis (LCA) patients produced improvements in 12 children and young adults. The same researchers then conducted an animal study that found that a second injection into the previously untreated eye, was safe and effective with no signs of interference from immune reactions from the earlier injection.

The Congress of the French Ophthalmology Society, SFO, will take place at the Palais des Congres, 2 place de la Porte Maillot, Paris, France, 8-11 May 2010.

New research is emerging from the Vanderbilt Eye Institute that indicates the first sign of injury in glaucoma occurs in the brain.

A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.

San Francisco?Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.